Figure 6.

Validation of pulldown eSimoa pipeline in clinical samples. Plasma samples spiked with PANC‐1 EVs at varying EV concentrations were measured using the pulldown eSimoa pipeline. Biotinylated antibodies specific to CD81 were utilized to label EVs. Subsequently, streptavidin‐conjugated beads were used to capture the biotinylated EVs. The captured CD81‐positive EVs were then lysed and analyzed using the a) pan‐RAS and b) KRAS^G12D eSimoa assays. The lowest detectable PACN‐1 EV spiking concentration was 1.5 × 10⁸ EV mL⁻¹ for RAS and 7.2 × 10⁸ EV mL⁻¹ for KRAS^G12D. All measurements were performed in duplicate. The dotted lines locate the LOD of the assay.